Does Rallies show Form 4 insider transactions for CMPS?

Yes. Rallies tracks CMPS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CMPS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CMPS. It does not provide personalized investment advice.

CMPS (COMPASS Pathways Plc American Depository Shares) Stock Analysis - Insider Trades

COMPASS Pathways Plc American Depository Shares (CMPS) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPS trades at $10.87 with a market cap of $1.43B and a P/E ratio of -3.47. CMPS moved +8.04% today. Year to date, CMPS is +65.70%; over the trailing twelve months it is +135.28%. Its 52-week range spans $2.25 to $11.65. Analyst consensus is strong buy with an average price target of $23.50. Rallies surfaces CMPS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CMPS stock inside the company?

Recent CMPS insider activity includes ATAI Life Sciences N.V. sold 2.66M, Malievskaia Ekaterina sold 8.90K, Malievskaia Ekaterina sold 8.90K, Goldsmith George Jay sold 8.90K, and Goldsmith George Jay sold 8.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CMPS Key Metrics

Key financial metrics for CMPS
Metric	Value
Price	$10.87
Market Cap	$1.43B
P/E Ratio	-3.47
EPS	$-3.08
Dividend Yield	0.00%
52-Week High	$11.65
52-Week Low	$2.25
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-287.86M
Gross Margin	0.00%

Recent CMPS Insider Trades

ATAI Life Sciences N.V. sold 2.66M (~$16.09M) on Sep 26, 2024.
Malievskaia Ekaterina sold 8.90K (~$70.38K) on May 21, 2024.
Malievskaia Ekaterina sold 8.90K (~$70.38K) on May 21, 2024.
Goldsmith George Jay sold 8.90K (~$70.38K) on May 21, 2024.
Goldsmith George Jay sold 8.90K (~$70.38K) on May 21, 2024.

Latest CMPS News

Compass Pathways Confirms Full Phase IIb Enrollment and Mid-2027 Cash Runway — May 14, 2026
Compass Pathways Shares Hit Two-Year High After Q1 Clinical Advances — May 13, 2026
Compass Pathways Gains 25% After FDA Rolling NDA Review and Priority Voucher — Apr 27, 2026
Cannabis Roundup: Jushi’s $160M Loan, Auxly’s 24% Growth, Canopy Leadership — Mar 29, 2026
Compass Pathways’ Psilocybin Phase 3 Shows 3.8-Point MADRS Benefit — Mar 9, 2026

CMPS Analyst Consensus

12 analysts cover CMPS: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.50.

Common questions about CMPS

Who is trading CMPS stock inside the company?: Recent CMPS insider activity includes ATAI Life Sciences N.V. sold 2.66M, Malievskaia Ekaterina sold 8.90K, Malievskaia Ekaterina sold 8.90K, Goldsmith George Jay sold 8.90K, and Goldsmith George Jay sold 8.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CMPS?: Yes. Rallies tracks CMPS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CMPS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CMPS. It does not provide personalized investment advice.